<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CEFOTETAN DISODIUM</span><br/>(sef'oh-tee-tan)<br/><span class="topboxtradename">Cefotan<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">third-generation cephalosporin</span><br/><b>Prototype: </b>Cefotaxime sodium<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>1 g, 2 g injection</p>
<h1><a name="action">Actions</a></h1>
<p>Semisynthetic beta-lactam antibiotic, classified as a third-generation cephalosporin. Preferentially binds to one or more
         of the penicillin-binding proteins (PBP) located on cell walls of susceptible organisms. This inhibits third and final stage
         of bacterial cell wall synthesis, thus killing the bacterium. Generally less active against susceptible <i>Staphylococci</i> than first generation cephalosporins are but has broad spectrum of activity against gram-negative bacteria when compared
         to first and second generation cephalosporins.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Spectrum of activity is like that of cefotaxime including <i>Escherichia coli,</i>
<i>Klebsiella</i> sp, <i>Enterobacter</i> sp, <i>Proteus</i> sp, <i>Streptococcus pneumoniae</i>, <i>Staphylococcus aureus</i>, penicillinase- and nonpenicillinase-producing <i>Haemophilus influenzae, Salmonella, Shigella, Neisseria gonorrhoeae,</i> and many anaerobes. Generally inactive against <i>Pseudomonas aeruginosa</i>. It is active against the <i>Enterobacteriaceae</i> and anaerobes, and shows moderate activity against gram-positive organisms. Effectively treats bone and joint infections,
         gynecologic and intra-abdominal infections, lower respiratory tract infections, skin infections, urinary tract infections,
         and is used for surgical prophylaxis, reducing or eliminating infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Infections caused by susceptible organisms in urinary tract, lower respiratory tract, skin and skin structures, bones and
         joints, gynecologic tract; also intra-abdominal infections, bacteremia, and perioperative prophylaxis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to cephalosporins and related beta-lactam antibiotics; pregnancy (category B).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g q12h<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM</span> 4080 mg/kg/d divided q12h (max: 6 g/d)<br/><br/><span class="indicationtitle">Surgical Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM</span> 12 g 3060 min before surgery<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular</span><br/><ul>
<li>For IM reconstitution (follow manufacturer's directions for selection of diluent), add 2 mL diluent to 1 g vial; yields approximately
            2.4 mL (375 mg/mL).
         </li>
<li>For IM administration, inject well into body of large muscle such as upper outer quadrant of buttock (gluteus maximus).</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV administration to infants and children: Verify correct IV concentration and rate of infusion with physician.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Dilute each 1 g with 10 mL of sterile water for injection.   <span class="methodtype">Intermittent:</span>  Following reconstitution, dilute each 1 g with 50100 mL of D5W or NS.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 35 min.   <span class="methodtype">Intermittent:</span> Give a single dose over 30 min. For IV infusion, solution may be given for longer period of time through tubing system through
                  which other IV solutions are being given.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">aminoglycosides</span>, <b>doxapram,</b>
<span class="classification">heparin</span>, <b>promethazine,</b>
<span class="classification">tetracyclines</span>. <span class="incompattype">Y-site:</span>
<span class="classification">aminoglycosides</span>, <b>promethazine,</b>
<b>vancomycin,</b>
<b>vinorelbine.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Protect sterile powder from light; store at 22° C (71.6° F) or less; remains stable 24 mo after date of manufacture.
            May darken with age, but potency is unaffected. Reconstituted solutions: stable for 24 h at 25° C (77° F); 96 h
            when refrigerated at 5° C (41° F); or at least 1 wk when frozen at 20° C (4° F).
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Fever, chills, injection site pain, inflammation, disulfiram-like reaction. <span class="typehead">GI:</span> Nausea, vomiting, <span class="speceff-common">diarrhea,</span> abdominal pain, antibiotic-associated colitis. <span class="typehead">Hematologic:</span> Thrombocytopenia, prolongation of bleeding time or prothrombin time. <span class="typehead">Skin:</span> Rash, pruritus. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause falsely elevated <span class="alt">serum</span> or <span class="alt">urine creatinine</span> values <span class="alt">(Jaffe reaction).</span> False-positive reactions for <span class="alt">urine glucose</span> have not been reported using <span class="alt">copper sulfate reduction methods,</span> e.g., <span class="alt">Benedict's,</span>
<span class="alt">Clinitest;</span> however, since it has occurred with other cephalosporins, it may be advisable to use <span class="alt">glucose oxidase tests</span>
<span class="alt">(Clinistix,</span>
<span class="alt">TesTape,</span>
<span class="alt">Diastix).</span> Positive <span class="alt">direct antiglobulin</span>
<span class="alt">(Coombs')</span>
<span class="alt">test</span> results may interfere with <span class="alt">hematologic studies</span> and <span class="alt">cross-matching</span> procedures.
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Probenecid</b> decreases renal elimination of cefotetan; <b>alcohol</b> produces disulfiram reaction. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Peak:</span> 1.53 h after IM. <span class="typehead">Distribution:</span> Poor CNS penetration; widely distributed to body tissues and fluids, including bile, sputum, prostatic and peritoneal fluids;
      crosses placenta. <span class="typehead">Elimination:</span> 5181% excreted unchanged in urine; 20% excreted in bile; small amount excreted in breast milk. <span class="typehead">Half-Life:</span> 180270 min. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Determine history of hypersensitivity to cephalosporins and penicillins, and other drug allergies, before therapy begins.</li>
<li>Lab tests: Perform culture and sensitivity studies before initiation of therapy and during therapy, as indicated. Therapy
            may begin pending test results. Perform periodic hematologic studies (including PT/INR and PTT) and evaluation of renal function,
            especially if cefotetan dose is high or if therapy is prolonged in order to recognize symptoms of nephrotoxicity and ototoxicity
            (see Appendix F).
         </li>
<li>Report onset of loose stools or diarrhea. If diarrhea is severe, suspect pseudomembranous colitis (see Appendix F) caused
            by <i>Clostridium difficile</i>. Check temperature. Report fever and severe diarrhea to physician; drug should be discontinued.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly S&amp;S of superinfection (see Appendix F).</li>
<li>Report loose stools or diarrhea.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>